| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4001625 | Urologic Oncology: Seminars and Original Investigations | 2007 | 7 Pages |
Abstract
The combined cytotoxicity of paclitaxel and 5-fluorouracil is schedule dependent. It is feasible to administer weekly paclitaxel and high-dose 5-fluorouracil infusions in patients with hormone-refractory prostate cancer. Our findings may serve as an important rationale for future trial design.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Chia-Chi M.D., Ph.D., Chih-Hung M.D., Ph.D., Tzyh-Chyuan Ph.D., Ann-Lii M.D., Ph.D., Chao-Yuan M.D., Kuo-How M.D., Jun M.D., Yeong-Shiau M.D., Ph.D.,